Lexeo Therapeutics, Inc. Form 4 Filings

Lexeo Therapeutics, Inc. (LXEO) reported that Chief Executive Officer and director Richard Nolan Townsend sold 3,345 shares of Common Stock on 2026-08-18. The sale, at a weighted average price of $4.9512 per share (individual trades ranged from $4.83 to $5.01), was to cover tax obligations on the release of restricted stock units (RSUs). Following this transaction, he directly holds 374,472 shares of Lexeo common stock, which includes 242,911 RSUs.

Lexeo Therapeutics, Inc. (LXEO) reported that Chief Operating Officer Jose Manuel Otero sold 1,304 shares of common stock on August 18, 2026 at a weighted average price of $4.9571 per share. The sale was made to cover tax obligations arising from the release of restricted stock units. Following this transaction, Otero directly holds 136,178 shares of Lexeo common stock, including 97,026 Restricted Stock Units.

Lexeo Therapeutics’ Chief Financial Officer Louis Edward Tamayo reported a mix of stock grant and related share sale. On June 29, 2026, he received an award of 12,000 shares of common stock at no cost as compensation.

On July 1, 2026, he sold 4,641 shares of common stock at a weighted average price of $4.49 per share. A footnote explains this sale was made to cover tax obligations on the release of performance Restricted Stock Units (RSUs), meaning it was a tax-related disposition rather than a discretionary portfolio sale.

Following these transactions, he directly holds 97,024 shares of common stock, which include 89,665 RSUs. Each RSU represents a contingent right to receive one share of Lexeo common stock in the future, typically upon meeting vesting conditions.

Lexeo Therapeutics, Inc. chief operating officer Jose Manuel Otero reported two equity transactions in company common stock. On June 29, he received 12,060 shares at no cost as a grant or award, increasing his direct holdings. On July 1, he sold 4,666 shares at a weighted average price of $4.48 per share to cover tax obligations related to the release of performance Restricted Stock Units, according to the footnotes. After these transactions, he directly holds 137,482 shares, which include 100,621 RSUs, indicating the sale represents a small portion of his overall position.

Lexeo Therapeutics Chief Medical Officer Narinder Pal Bhalla reported a compensation-related stock grant and a tax-related share sale. On June 29, 2026, he received 55,000 shares of common stock as a grant or award. On July 1, 2026, 22,306 shares of common stock were sold at a weighted average price of $4.42 per share to cover tax obligations on the release of performance Restricted Stock Units. After these transactions, he directly held 82,194 shares of common stock, including 49,500 RSUs, each representing a contingent right to receive one share.

Lexeo Therapeutics, Inc. Chief Executive Officer Richard Nolan Townsend reported two equity transactions involving the company’s common stock. He received a grant of 67,000 shares of common stock on June 29, 2026 at no cost as a compensation-related award. On July 1, 2026, he sold 25,947 shares at a weighted average price of $4.48 per share, with prices ranging from $4.3402 to $4.7507, specifically to cover tax obligations tied to the release of performance restricted stock units. After the sale, he directly owned 377,817 shares of common stock, which includes 252,130 restricted stock units, indicating he retains a substantial equity position in the company.

Lexeo Therapeutics director Steven Altschuler received a grant of options covering 35,000 shares of Common Stock. The stock options have an exercise price of $4.70 per share and expire on June 24, 2036. All 35,000 underlying shares vest and become exercisable on the earlier of one year after the grant date or the next annual meeting of stockholders, as long as he remains in continuous service. Following this award, he holds 35,000 stock options directly, and the transaction reflects a compensation-related grant rather than an open-market purchase.

Lexeo Therapeutics, Inc. director Mette Kirstine Agger received a grant of stock options covering 35,000 shares of common stock. The options have an exercise price of $4.70 per share and expire on June 24, 2036. According to the vesting terms, all 35,000 underlying shares will vest and become exercisable on the earlier of one year after the grant date or the next annual meeting of stockholders, as long as she continues in service through that date. After this grant, she holds stock options for 35,000 shares directly.

Lexeo Therapeutics director Brenda Cooperstone received a grant of stock options covering 35,000 shares of common stock. The options have an exercise price of $4.70 per share and expire on June 24, 2036. All 35,000 underlying shares vest on the earlier of one year after the grant date or the next annual meeting of stockholders, subject to her continuous service, leaving her with 35,000 derivative securities following this award.

Lexeo Therapeutics director Reinaldo M. Diaz received a grant of stock options as equity compensation. He was awarded options to acquire 35,000 shares of common stock at an exercise price of $4.70 per share, with all shares underlying the option scheduled to vest and become exercisable on the earlier of one year after the grant date or the next annual meeting of stockholders, conditioned on his continuous service.

Lexeo Therapeutics director Tolga Tanguler received a new stock option award. The grant covers 35,000 options to buy Lexeo common stock at an exercise price of $4.70 per share and will expire on June 24, 2036.

According to the vesting terms, 100% of the shares underlying the option will vest, and become exercisable, on the earlier of one year after the grant date or the next annual meeting of stockholders, subject to his continuous service. Following this award, he holds 35,000 stock options directly.

Lexeo Therapeutics, Inc. director Timothy Van Hauwermeiren received a grant of stock options covering 35,000 shares of common stock. The options have an exercise price of $4.70 per share and expire on June 24, 2036. All 35,000 underlying shares will vest and become exercisable on the earlier of one year after the grant date or the next annual meeting of stockholders, assuming he continues in service through that date. Following this award, he holds options on 35,000 shares directly.

Lexeo Therapeutics, Inc. director Paula H. Cholmondeley reported receiving a stock option grant covering 35,000 shares of common stock. The option has an exercise price of $4.7000 per share and expires on June 24, 2036. According to the disclosure, all 35,000 underlying shares will vest and become exercisable on the earlier of one year after the grant date or the next annual meeting of stockholders, provided she continues in service through that date.

Lexeo Therapeutics, Inc. Chief Operating Officer Jose Manuel Otero reported a sale of 1,302 shares of common stock on May 18, 2026 at a weighted average price of $5.074 per share. According to the filing, this sale was made to cover tax obligations arising from the release of restricted stock units.

After the transaction, Otero holds 130,088 shares of Lexeo common stock, which includes 100,621 Restricted Stock Units. The trade was reported as a direct ownership transaction and was executed in multiple trades at prices ranging from $5.06 to $5.11 per share.

Lexeo Therapeutics, Inc. Chief Executive Officer Richard Nolan Townsend reported an open-market sale of 3,342 shares of common stock at a weighted average price of $5.0649 per share on May 18, 2026. The footnotes state this sale was made to cover tax obligations arising from the release of restricted stock units, indicating it was a tax-related transaction rather than a discretionary portfolio move. Following the sale, he directly holds 336,764 shares of Lexeo common stock, which includes 252,130 restricted stock units.

Lexeo Therapeutics, Inc. director Laura Sepp-Lorenzino received a grant of stock options covering 50,000 shares of common stock. The options have an exercise price of $5.81 per share and expire on April 27, 2036. They vest in equal annual installments over three years, so the award becomes fully exercisable on the third anniversary of the grant date, subject to her continuous service with the company. After this grant, she holds options for 50,000 underlying shares directly.

Lexeo Therapeutics, Inc. Chief Executive Officer Richard Nolan reported an open-market sale of 55,000 shares of common stock at a weighted average price of $5.6934 per share. The sale on April 6, 2026 was made under a pre-arranged Rule 10b5-1 trading plan.

Following this transaction, Nolan directly holds 340,106 shares of Lexeo common stock, which includes 261,349 Restricted Stock Units that may convert into shares if vesting conditions are satisfied.

Lexeo Therapeutics Chief Executive Officer Richard Nolan Townsend acquired 2,623 shares of common stock at $2.644 per share through the company’s 2023 Employee Stock Purchase Plan, in a transaction exempt under Rule 16b-3(c) and 16b-3(d). Following this award, he directly holds 395,106 shares, including 261,349 restricted stock units.

Lexeo Therapeutics, Inc. Chief Operating Officer Jose Manuel Otero acquired 5,930 shares of common stock on March 13, 2026 at $2.644 per share through the company’s 2023 Employee Stock Purchase Plan. After this transaction, he holds 131,390 shares in total, including 104,216 restricted stock units, in a transaction exempt under Rule 16b-3(c) and 16b-3(d).

Lexeo Therapeutics Chief Operating Officer Jose Manuel Otero reported an open-market sale of 3,016 shares of common stock on February 18, 2026 at a weighted average price of $6.3972 per share. The sale was made to cover tax obligations on the release of restricted stock units. After this transaction, Otero beneficially owned 125,460 shares, including 104,216 restricted stock units.

Lexeo Therapeutics, Inc. Chief Executive Officer Richard Nolan Townsend reported an open-market sale of 10,173 shares of common stock at a weighted average price of $6.382 per share. According to the footnotes, this sale was made to cover tax obligations on the release of restricted stock units. Following the transaction, he directly holds 392,483 shares, which include 261,349 restricted stock units.

Lexeo Therapeutics, Inc. Chief Operating Officer Jose Manuel Otero corrected a prior insider trade report and detailed a small tax-related sale of shares. An earlier Form 4 had mistakenly stated that a sale to cover tax obligations occurred on August 18, 2025. This amendment clarifies that the open-market sale of 721 shares of common stock actually took place on November 18, 2025 at a weighted average price of $9.27 per share, executed in multiple trades between $9.09 and $9.37. The sale was made solely to cover tax obligations from the release of restricted stock units. After this transaction, Otero directly owns 63,476 shares of Lexeo Therapeutics common stock, including 47,733 RSUs, so his overall stake in the company remains largely unchanged.

Lexeo Therapeutics’ Chief Medical Officer Narinder Pal Bhalla received new equity awards in the form of stock options and restricted stock units. On February 13, 2026, he was granted 297,000 stock options with a $6.31 exercise price and 49,500 RSUs, both at no cash cost to him.

The option grant vests with 25% of the underlying shares becoming exercisable on January 20, 2027, and the remaining 75% vesting in equal monthly installments over the following three years, contingent on continuous service. The RSUs vest 25% on February 15, 2027, with the rest vesting in equal quarterly installments thereafter, also subject to continued service.

Lexeo Therapeutics CEO Townsend Richard Nolan received new equity awards on February 4, 2026. He was granted 161,665 restricted stock units (RSUs), each representing one share of common stock, at no purchase price. After this grant, he beneficially owned 402,656 shares of common stock, including 290,022 RSUs.

He was also granted a stock option for 646,665 shares of common stock with a $7.27 exercise price. For the RSUs, 25% vest on February 15, 2027, with the remainder vesting in equal quarterly installments. For the option, 25% vests on February 4, 2027, with the balance vesting monthly thereafter, all subject to his continued service.

Lexeo Therapeutics granted its Chief Operating Officer, Jose Manuel Otero, new equity awards. On February 4, 2026, he received 65,000 shares of Common Stock in the form of restricted stock units at a price of $0 per share, bringing his beneficially owned Common Stock to 128,476 shares, including 112,733 RSUs.

He was also granted a stock option for 260,000 shares of Common Stock at an exercise price of $7.27 per share. For this option, 25% of the shares vest and become exercisable on February 4, 2027, with the remaining shares vesting in equal monthly installments over the following period, subject to his continued service. For the RSUs, 25% vest on February 15, 2027, with the rest vesting in equal quarterly installments on Lexeo’s standard quarterly vesting dates, also subject to continued service.

Lexeo Therapeutics, Inc.’s Chief Financial Officer Louis Edward Tamayo reported new equity awards. On February 4, 2026, he received 44,665 shares of Common Stock as restricted stock units (RSUs) at $0 per share, bringing his directly owned Common Stock to 89,665 shares.

The RSUs vest over time: 25% on February 15, 2027, with the remaining RSUs vesting in 1/16th quarterly installments on the company’s standard vesting dates, subject to continued service. He was also granted a stock option to buy 226,665 shares of Common Stock at an exercise price of $7.27 per share, expiring on February 3, 2036. For this option, 25% of the underlying shares vest and become exercisable on February 4, 2027, with the rest vesting in 1/48th monthly installments, also subject to continuous service.

Lexeo Therapeutics, Inc. (LXEO) CEO insider transaction shows a small sale of shares by the company’s chief executive officer and director. On 11/18/2025, the reporting person sold 1,127 shares of common stock in a single reported transaction at a weighted average price of $9.27 per share.

The company notes that the sale was made to cover tax obligations arising from the release of restricted stock units, which is a common administrative transaction for equity compensation. After this sale, the reporting person beneficially owned 240,991 shares of Lexeo common stock, including 128,357 restricted stock units, indicating that the individual continues to hold a substantial equity position in the company.

Lexeo Therapeutics, Inc. reported an insider stock sale by its Chief Medical Officer. On 11/18/2025, the officer sold 615 shares of common stock at a weighted average price of $9.27 per share, coded as a sale transaction. The company notes this sale was made to cover tax obligations related to the release of restricted stock units.

After this transaction, the officer beneficially owned 72,646 shares of Lexeo common stock, which includes 58,866 restricted stock units. The filing confirms this was a Form 4 filed by a single reporting person in the capacity of an officer.

Lexeo Therapeutics, Inc. (LXEO) reported an insider transaction by its Chief Development Officer. On 11/18/2025, the officer sold 386 shares of common stock at a weighted average price of $9.27 per share. The company notes this was a sale to cover tax obligations arising from the release of restricted stock units (RSUs), rather than an open-market discretionary sale.

After this transaction, the officer beneficially owned 65,476 shares of Lexeo common stock, which the filing states includes 48,098 RSUs. The sale price resulted from multiple trades executed in a price range from $9.09 to $9.37 per share.

Lexeo Therapeutics (LXEO) Chief Legal Officer Form 4 filing reports a small insider sale tied to tax obligations. On 11/18/2025, the officer sold 549 shares of common stock in a sale to cover taxes due upon the release of restricted stock units. The weighted average sale price was $9.27 per share, based on multiple trades between $9.09 and $9.37.

After this transaction, the officer beneficially owns 68,381 shares of Lexeo Therapeutics common stock, which includes 49,607 restricted stock units. The filing states that detailed trade‑by‑trade pricing information will be provided upon request to the SEC staff, the company, or any security holder.

Lexeo Therapeutics, Inc. (LXEO) reported an insider transaction by its Chief Technical Officer on a Form 4. The officer sold 721 shares of common stock on 08/18/2025 at a weighted average price of $9.27 per share. The sale was made to cover tax obligations arising from the release of restricted stock units (RSUs). After this transaction, the officer beneficially owned 63,476 shares of Lexeo common stock, which includes 47,733 RSUs.

Lexeo Therapeutics (LXEO) insider filing: the Chief Development Officer reported equity transactions on a Form 4. On 10/15/2025, the officer acquired 10,890 shares of Common Stock at $0, reflecting the release of RSUs. On 10/17/2025, the officer sold 3,844 shares at a weighted average price of $8.935 (executed between $8.53 and $9.52) and 44 shares at a weighted average price of $9.561 (executed between $9.53 and $9.59). The filing states the sales were to cover tax obligations upon RSU release. Following these transactions, the officer beneficially owned 65,862 shares directly, which includes 49,138 RSUs, each representing a right to receive one share.

Lexeo Therapeutics (LXEO) insider activity: the Chief Legal Officer reported acquiring 9,900 shares of common stock on 10/15/2025 at $0, and selling shares to cover tax obligations on released RSUs.

On 10/17/2025, the officer sold 3,486 shares at a weighted average price of $8.935 (trades ranged from $8.53 to $9.52) and 40 shares at a weighted average price of $9.561 (trades ranged from $9.53 to $9.59). Following these transactions, beneficial ownership was 68,930 shares, which includes 51,092 RSUs, with each RSU representing a right to one share.

Lexeo Therapeutics (LXEO): insider transaction disclosed. The company’s Chief Technical Officer filed a Form 4 showing 5,940 shares of common stock acquired on 10/15/2025 at a price of $0. Following this, sales on 10/17/2025 totaled 2,091 shares at a weighted average price of $8.935 and 24 shares at a weighted average price of $9.561, with both ranges detailed in the notes. The filing states the sales represent shares sold to cover tax obligations on the release of RSUs.

After these transactions, the reporting person beneficially owned 64,197 shares directly, which includes 49,687 RSUs, each representing a contingent right to one share of common stock.

Lexeo Therapeutics (LXEO) reported insider activity by its Chief Medical Officer on a Form 4. On 10/15/2025, 9,570 shares of Common Stock were acquired at $0 upon the release of Restricted Stock Units. On 10/17/2025, the officer sold 3,344 shares at a weighted average price of $8.935 and 38 shares at a weighted average price of $9.561; the filing states these sales were to cover tax obligations related to the RSU release.

After the transactions, beneficial ownership was 73,261 shares, which includes 60,546 RSUs.

Lexeo Therapeutics (LXEO) reported insider activity by its Chief Executive Officer and Director. On 10/15/2025, the reporting person acquired 33,000 shares of Common Stock at $0 upon RSU release. On 10/17/2025, shares were sold to cover taxes in open market transactions: 12,985 shares at a weighted average price of $8.935 and 148 shares at a weighted average price of $9.561. Following these transactions, beneficial ownership stands at 242,118 shares, which includes 131,092 RSUs, held directly.